CTI BioPharma (CTIC) Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis with Severe Thrombocytopenia
- Wall Street drops as bargain-hunting loses steam
- Netflix (NFLX) Stock Tanks 19% on Paid Net Additions Miss & Lower Guidance
- Peloton (PTON) Warns for Q2 But Stock Rallies After-Hours as Worst Case Avoided
- Morgan Stanley Sees Apple (AAPL) Beating December Quarter Views But Says Upside Largely Priced In
- Ford (F) Stock Extends Losses in Pre Market as Jefferies Downgrades to Hold, Analyst Says Stock is 'Missing a New Angle'
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a baseline platelet count of <50 × 109/L. The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to February 28, 2022.
In the second quarter of 2021, the FDA granted priority review for CTI's NDA for patients with myelofibrosis with a PDUFA date of November 30, 2021. In the course of product labeling discussions, the FDA requested additional clinical data, which was submitted to the agency on November 24, 2021. Earlier today, the FDA informed the Company that it considers the data submission to constitute a "major amendment" to the NDA and therefore the PDUFA date has been extended by three months to provide additional time for a full review of the submission. At the current time, CTI is not aware of any major deficiencies in the application.
"CTI is continuing to engage collaboratively and constructively with the FDA during review of our NDA," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "We are committed to providing patients suffering from cytopenic myelofibrosis with a new treatment option as soon as possible and are confident in pacritinib's potential to establish a new standard of care."
Pacritinib is a novel oral kinase inhibitor with specificity for JAK2, IRAK1 and CSF1R, without inhibiting JAK1. The NDA was accepted based on the data from the Phase 3 PERSIST-2 and PERSIST-1 and the Phase 2 PAC203 clinical trials, with a focus on the severely thrombocytopenic (platelet counts less than 50 x 109/L) patients enrolled in these studies who received pacritinib 200 mg twice a day, including both frontline treatment-naive patients and patients with prior exposure to JAK2 inhibitors. In the PERSIST-2 study, in patients with severe thrombocytopenia who were treated with pacritinib 200 mg twice a day, 29% of patients had a reduction in spleen volume of at least 35%, compared to 3% of patients receiving the best available therapy, which included ruxolitinib; 23% of patients had a reduction in total symptom scores of at least 50%, compared to 13% of patients receiving the best available therapy. In the same population of patients treated with pacritinib, adverse events were generally low grade, manageable with supportive care, and rarely led to discontinuation. Platelet counts and hemoglobin levels were also stabilized.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regulus Therapeutics (RGLS) Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429
- bluebird bio (BLUE) FDA Extensions Likely Not an Issue with the BLA - Morgan Stanley
- Ecolab (ECL) Guides Q4, Expects Low-Teens Adjusted EPS Growth in Full-Year 2022
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot FDA News, Management Comments
Related EntitiesDefinitive Agreement, PDUFA, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!